Biodesix closes $20M Series D

Broomfield, CO-based Biodesix has closed on a $20 million Series D financing led by existing investors. The new capital will support ongoing commercialization activities for the company's first product, VeriStrat, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer. 

The funding also will support the company's ongoing collaborations with several biotechnology and pharmaceutical firms seeking diagnostics to identify the most appropriate patients for their targeted oncology therapies, according to Biodesix CEO David Brunel. 

Biodesix was founded in 2005 and has been a leader in personalizing medicine by introducing VeriStrat, which helps physicians determine if a patient should receive treatment with erlotinib, an epidermal growth factor inhibitor.

- see the Biodesix release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.